Name | RG7834 |
Description | RG7834 (RO 7020322) is a highly selective and orally bioavailable inhibitor of HBV, targeting HBsAg, HBeAg, and HBV DNA with IC50s of 2.8 nM, 2.6 nM, and 3.2 nM, respectively, in dHepaRG Cells. |
In vitro | RG7834 ((S)-(+)-64) is a highly selective and orally bioavailable inhibitor of HBV, potently inhibiting HBV antigens (HBsAg and HBeAg) and HBV DNA with IC50s of 2.8, 2.6, and 3.2 nM, respectively, in dHepaRG cells. RG7834 exhibits no activity against CYP3A4, CYP2D6, CYP2C9 (IC50s >50 μM) or the hERG channel. |
In vivo | In HBV-infected human liver chimeric uPA-SCID mice,RG7834 shows anti-HBV efficacy. RG7834 (2, 14.5 mg/kg, p.o.) exhibits good oral bioavail ability, and with a half-life of 4.9 h in mice. |
Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 125 mg/mL (311.37 mM), Sonication is recommended.
|
Keywords | Hepatitis B virus | RO7020322 | RG 7834 | inhibit | Inhibitor | RG-7834 | RG7834 | RO-7020322 | HBV |
Inhibitors Related | Doxorubicin hydrochloride | Osthole | RO8191 | Cetylpyridinium Chloride | Tenofovir Disoproxil Fumarate | Thiamine hydrochloride | 4,5-Dicaffeoylquinic acid | Vebicorvir | 4-Hydroxyacetophenone | Telbivudine | Tenofovir | Bifendate |
Related Compound Libraries | Bioactive Compound Library | ReFRAME Related Library | Anti-Viral Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Clinical Compound Library | Bioactive Compounds Library Max |